GlassScriptPhysician profile
Sharon Jackson
NPI 1043566383
$14,782.84
in general payments reported to CMS, 2019-2025
51 companies · $2,823 in 2025
The $2,823 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,277 · 2022: $3,217 · 2023: $3,363 · 2024: $3,102 · 2025: $2,823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,079 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200 · Education: $9.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,079.38 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
| Education | $9.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,081.49 | 2021-2025 | |
| Pfizer INC. | $1,249.55 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $1,248.46 | 2021-2025 | Nuplazid, Daybue |
| Novartis Pharmaceuticals Corporation | $963.48 | 2021-2025 | |
| Amgen INC. | $848.23 | 2021-2025 | Uplizna, Aimovig |
| Genzyme Corporation | $758.53 | 2021-2025 | |
| Ucb, INC. | $671.00 | 2021-2025 | Briviact, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $492.07 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Lilly USA, LLC | $402.34 | 2021-2025 | Amyvid, Kisunla, Emgality |
| Lundbeck LLC | $390.46 | 2021-2025 | Vyepti, Rexulti |
| Argenx US, INC. | $382.24 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Biohaven Pharmaceutical Holding Company LTD. | $337.91 | 2022 | |
| Astellas Pharma US INC | $320.29 | 2021-2025 | Veozah, Myrbetriq |
| Emd Serono, INC. | $302.04 | 2021-2024 | Mavenclad |
| Takeda Pharmaceuticals U.S.A., INC. | $255.76 | 2023-2024 | Hyqvia, Gammagard |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.